Vaxxinity (VAXX) Competitors $0.03 +0.02 (+200.00%) As of 08/22/2025 10:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. BCAB, ELEV, CING, RLYB, TRIB, ADAP, AYTU, MBRX, QTTB, and FNCHShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include BioAtla (BCAB), Elevation Oncology (ELEV), Cingulate (CING), Rallybio (RLYB), Trinity Biotech (TRIB), Adaptimmune Therapeutics (ADAP), Aytu BioPharma (AYTU), Moleculin Biotech (MBRX), Q32 Bio (QTTB), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Its Competitors BioAtla Elevation Oncology Cingulate Rallybio Trinity Biotech Adaptimmune Therapeutics Aytu BioPharma Moleculin Biotech Q32 Bio Finch Therapeutics Group BioAtla (NASDAQ:BCAB) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation. Do analysts prefer BCAB or VAXX? BioAtla currently has a consensus price target of $5.00, indicating a potential upside of 1,303.71%. Given BioAtla's stronger consensus rating and higher probable upside, analysts clearly believe BioAtla is more favorable than Vaxxinity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in BCAB or VAXX? 77.2% of BioAtla shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 11.2% of BioAtla shares are owned by company insiders. Comparatively, 64.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, BCAB or VAXX? BioAtla has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -24.16, meaning that its stock price is 2,516% less volatile than the S&P 500. Does the media prefer BCAB or VAXX? In the previous week, BioAtla had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for BioAtla and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 beat BioAtla's score of -0.31 indicating that Vaxxinity is being referred to more favorably in the news media. Company Overall Sentiment BioAtla Neutral Vaxxinity Neutral Is BCAB or VAXX more profitable? Vaxxinity's return on equity of 0.00% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -1,177.18% -137.51% Vaxxinity N/A N/A N/A Which has stronger valuation & earnings, BCAB or VAXX? Vaxxinity has lower revenue, but higher earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M1.90-$69.78M-$1.10-0.32VaxxinityN/AN/A-$56.93M-$0.45-0.07 SummaryVaxxinity beats BioAtla on 8 of the 13 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.80M$833.52M$5.81B$9.76BDividend YieldN/A4.84%4.39%4.06%P/E Ratio-0.071.1831.3626.05Price / SalesN/A152.90387.8788.42Price / CashN/A19.5638.0259.36Price / Book0.276.649.536.60Net Income-$56.93M-$4.94M$3.26B$265.65M7 Day PerformanceN/A1.85%2.14%2.00%1 Month PerformanceN/A3.06%3.22%0.46%1 Year PerformanceN/A12.25%30.19%18.88% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.03+200.0%N/A+200.0%$3.80MN/A-0.0790Gap UpBCABBioAtla2.2839 of 5 stars$0.37+0.8%$5.00+1,240.5%-81.2%$21.79M$11M-0.3460Gap UpELEVElevation Oncology1.3522 of 5 stars$0.37flat$2.62+616.9%N/A$21.62MN/A-0.4540CINGCingulate2.4351 of 5 stars$4.08-0.1%$26.00+536.6%-56.8%$21.53MN/A-0.4820Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionRLYBRallybio3.2181 of 5 stars$0.51+1.3%$10.00+1,860.8%-44.6%$21.31M$640K-0.5440News CoverageAnalyst UpgradeShort Interest ↓TRIBTrinity Biotech1.433 of 5 stars$1.16+2.7%N/A-21.5%$21.12M$61.56M-0.40480Upcoming EarningsGap DownADAPAdaptimmune Therapeutics2.07 of 5 stars$0.08+3.3%$1.35+1,604.5%-95.3%$20.89M$179.64M-0.29490Insider TradeGap UpAYTUAytu BioPharma3.1266 of 5 stars$2.30+2.0%$10.00+335.7%-9.8%$20.60M$81.66M-3.19160MBRXMoleculin Biotech2.75 of 5 stars$0.68+2.1%$4.00+491.7%-76.3%$20.42MN/A0.0020QTTBQ32 Bio2.3757 of 5 stars$1.67-0.9%$12.17+630.7%-95.2%$20.31M$1.16M-0.3939News CoverageShort Interest ↓Gap DownFNCHFinch Therapeutics GroupN/A$12.25+0.1%N/A+17.2%$19.67MN/A-1.39190 Related Companies and Tools Related Companies BioAtla Competitors Elevation Oncology Competitors Cingulate Competitors Rallybio Competitors Trinity Biotech Competitors Adaptimmune Therapeutics Competitors Aytu BioPharma Competitors Moleculin Biotech Competitors Q32 Bio Competitors Finch Therapeutics Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access